特利加压素治疗失代偿期乙型肝炎肝硬化患者消退腹水的作用及对肝肾功能的影响

doi:10.3969/j.issn.1672-5069.2016.06.012

摘要/Abstract

摘要： 目的探讨特利加压素对失代偿期乙型肝炎肝硬化患者肝肾功能的影响及对腹水的治疗作用。方法回顾性分析2014年8月至2016年4月安徽省立医院肝脏外科收治的50例失代偿期乙型肝炎肝硬化患者，按其处置方式的不同分为特利加压素处理组（n=25）和传统处理组（n=25），比较两组患者治疗后1 d、3 d、7 d血清谷丙转氨酶、谷草转氨酶、总胆红素、碱性磷酸酶、肌酐、尿素氮等肝肾功能指标及24 h尿量和腹围的变化。结果治疗后3 d和7 d，特利加压素治疗患者血清肌酐水平为（100.88±28.51）μmol/L和（95.28±25.34）μmol/L，显著低于传统处理组【分别为（124.34±19.88）μmol/L和（113.99±26.89）μmol/L，P＜0.05】；尿素氮水平为（10.13±4.76）μmol/L和（9.05±4.53）μmol/L，低于传统处理组【分别为（13.12±5.28）μmol/L和（12.34±5.99）μmol/L，P＜0.05】；24 h尿量为（1825.6±613.34） ml和（1990.8±731.16）ml，显著多于传统处理组【（1334.42±542.33）ml和（1421.54±698.99）ml，P＜0.05】；腹围为（91.32±7.4）cm和（91.04±7.45）cm，显著小于传统治疗组【（96.28±6.89）cm和（96.55±7.99）cm，P＜0.05】。治疗7 d后，特利加压素组患者腹水好转率为76.0%（19/25），显著高于传统治疗组的40.0%(10/25，P＜0.05）；而两组患者血清谷丙转氨酶、谷草转氨酶、总胆红素、碱性磷酸酶等肝功能指标的变化，差异无统计学意义（P＞0.05）。结论对于失代偿期乙型肝炎肝硬化患者，特利加压素能有效改善其肾功能，减少腹水，预防肝肾综合征的发生，短期使用该药，对患者肝功能影响不大。

关键词: 失代偿期肝硬化, 特利加压素, 肝肾功能, 腹水

Abstract: Objiective To explore the therapeutic effect of telipressin in treatment of patients with decompensated cirrhosis resulting from chronic hepatitis B. Methods 50 patients with decompensated cirrhosis resulting from chronic hepatitis B were admitted to Anhui Provincial Hospital between August 2014 and June 2016. The patients were divided into telipressin treatment group（n=25） and traditional treatment group（n=25） accordng to the different treatment approaches. The urine volume，abdominal perimeter，and the serum levels of alanine aminotransferase（ALT），AST，total bilirubin，alkaline phosphatase（ALP），creatinine， urea nitrogen on day 1，3，7 after treatment were compared between the two groups. Results On day 3 and 7 after treatment，serum levels creatinine in telipressin treatment group were（100.88±28.51） μmol/L and （95.28±25.34） μmol/L，respectively，significantly lower than those in traditional treatment group [（124.34±19.88）μmol/L and （113.99±26.89） μmol/L，P＜0.05]；serum levels of urea nitrogen in telipressin treatment group were （10.13±4.76） μmol/L and（9.05±4.53） μmol/L，respectively，markedly lower than those in traditional treatment group[（13.12±5.28）μmol/L and （12.34±5.99） μmol/L，P＜0.05]；urine volumes in telipressin treatment group were （1825.6±613.34） ml and （1990.8±731.16） ml，respectively，much greater than those in traditional treatment group[（1334.42±542.33）ml and（1421.54±698.99） ml，P＜0.05]；abdominal perimeters in telipressin treatment group were（91.32±7.4） cm and（91.04±7.45） cm， respectively，smaller than those in traditional treatment group [（96.28±6.89）cm and （96.55±7.99） cm，P＜0.05]；after seven day treatment，ascites subsided in 76.0% in telipressin treatment group （19/25），much higher than 40.0% in patients in traditional treatment group（10/25，P＜0.05）；However，serum levels of ALT，AST，ALP，total bilirubin on day 3 and 7 after treatment were not significantly different between the two groups（P＞0.05）. Conclusion Terlipressin is effective for patients with decompensated cirrhosis resulting from chronic hepatitis B. The treatment can improve renal functions and decrease ascites.

Key words: Decompensated cirrhosis, Terlipressin, Hepatic and renal function, Ascites.

程亚，乔晓斐，荚卫东. 特利加压素治疗失代偿期乙型肝炎肝硬化患者消退腹水的作用及对肝肾功能的影响[J]. 实用肝脏病杂志, 2016, 19(6): 687-691.

Cheng Ya，Qiao Xiaofei，Jia Weidong.. Therapeutic effects of terlipressin in treatment of patients with decompensated cirrhosis resulting from chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 687-691.

参考文献

[1] Samuel D，Muller R，Alexander G，et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med，1993，329（25）:1842-1847.
[2] Ginés P，Quintero E，Arroyo V，et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology，1987，7（1）:122-128.
[3] Planas R，Montoliu S，Balleste B，et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol，2006，4（11）:1385-1394.
[4] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012．Hepatology，2013，57（4）:1651-1653．
[5] Angeli P，Fasolato S，Mazza E，et al. Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis:results of an open randomized clinical trial. Gut，2010，59（1）:98-104.
[6] Bernardi M. Optimum use of diuretics in managing ascites in patients with cirrhosis. Gut，2010，59（1）:10-11.
[7] Chan CC，Lee FY，Wang SS，et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats:Role of nitric oxide and prostaglandin. Hepatology，1999，30（3）:630-635.
[8] 王天才，张国. 特利加压素、垂体后叶素对正常及门脉高压兔门脉血流动力学影响的研究. 中华消化杂志，2002，22（10）:595-597.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[10] Ginès P，Schrier RW. Renal failure in cirrhosis. New Engl J Med，2010，362（1）:1279-1290.
[11] Sort P，Navasa M，Arroyo V，et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med，1999，341（6）:403-409.
[12] Shear L，Ching S，Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. New Engl J Med，1970，282（25）:1391-1396.
[13] Kiszka-Kanowitz M. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scan J Gastroenterol，2004，39（5）:486-492.
[14] Gines P，Guevara M，Arroyo V，et al. Hepatorenal syndrome. Lancet，2003，362（9398）:1819-1827.
[15] Sanyal AJ，Boyer T，Garcia-Tsao G，et al. A randomized，prospective，double-blind，placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology，2008，134（5）:1360-1368.
[16] Moreau R，Lebrec D. The use of vasoconstrictors in patients with cirrhosis:Type 1 HRS and beyond. Hepatology，2006，43（3）:385-394.
[17] Fimiani B，Guardia DD，Puoti C，et al. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function:A multicentric study. Eur J Intern Med，2011，22（6）:587-590.
[18] Angeli P，Lenz K，Ginès P，et al. EASL clinical practice guidelines on the management of ascites，spontaneous bacterial peritonitis，and hepatorenal syndrome in cirrhosis. J Hepatol，2010，53（3）:397-417.
[19] Salerno F，Guevara M，Bernardi M，et al. Refractory ascites: pathogenesis，definition and therapy of a severe complication in patients with cirrhosis. Liver Int，2010，30（7）:937-947.
[20] Salman TA，Edrees AM，El-Said HH，et al. Effect of different therapeutic modalities on systemic，renal，and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol，2016，28（7）:777-785.
[21] Fayed N，Refaat EK，Yassein TE，et al. Effect of perioperative terlipressin infusion on systemic，hepatic，and renal hemodynamics during living donor liver transplantation. J Crit Care，2013，28（5）:775-782.
[22] Sanyal AJ，Mathurin P，Nagy LA. Commonalities and distinctions between alcoholic and nonalcoholic fatty liver disease. Gastroenterology，2016，150（8）:1695-1697.
[23] Hong SH，Lee JM，Choi JH，et al. Perioperative assessment of terlipressin infusion during living donor liver transplantation. J Int Med Res，2012，40（1）:225-236.
[24] 李民，熊俊. 特利加压素控制肝癌肝切除术后腹腔积液形成的前瞻性研究. 中华消化外科杂志，2012，11（6）:518-521.
[25] Fahrner R，Patsenker E，De GA，et al. Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation，2014，97（9）:892-900.